CIK 0001541157 · Non-accelerated filer<br>Smaller reporting company
Akari Therapeutics Plc
Sign in to watch- Ticker
- AKTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- EIN
- 981034922
- Phone
- (929) 274-7510
- Business address
- 401 EAST JACKSON STREET, SUITE 3300, TAMPA, FL, 33602
- Former names
- Celsus Therapeutics Plc., Morria Biopharmaceuticals PLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-07 | Patel Samir Rashmikant Director | Option exercise · Pre-Funded Warrant to purchase American Depositary Shares | +1,209 | $32.00 | $39K | 0 |
| 2026-07-07 | Patel Samir Rashmikant Director | Option exercise · Pre-Funded Warrant to purchase ADSs | +15,466 | $16.16 | $250K | 0 |
| 2026-07-07 | Patel Samir Rashmikant Director | Option exercise · Pre-Funded Warrant to purchase ADSs | +5,799 | $16.16 | $94K | 0 |
| 2026-06-24 | Farag Kameel D. Interim CFO | Grant or award | +1,248 | $10.02 | $13K | 2,870 |
| 2026-06-24 | Farag Kameel D. Interim CFO | Grant or award | +1,395 | $9.32 | $13K | 4,265 |
| 2026-06-24 | Farag Kameel D. Interim CFO | Grant or award | +1,570 | $8.28 | $13K | 5,835 |
| 2026-06-24 | Farag Kameel D. Interim CFO | Grant or award | +2,539 | $5.12 | $13K | 8,374 |
| 2026-06-24 | Farag Kameel D. Interim CFO | Grant or award | +3,725 | $3.49 | $13K | 12,099 |
| 2026-06-24 | Farag Kameel D. Interim CFO | Grant or award | +7,353 | $3.74 | $28K | 19,452 |
| 2026-06-24 | Farag Kameel D. Interim CFO | Grant or award | +1,000 | $13.00 | $13K | 20,452 |
| 2026-06-24 | Gaslightwala Abizer CEO | Grant or award · Stock Option (Right to Buy) | +5,500 | 5,500 | ||
| 2026-06-24 | Gaslightwala Abizer CEO | Grant or award · Stock Option (Right to Buy) | +15,563 | 15,563 | ||
| 2025-12-16 | Neal James R Director | Purchase · Warrants to purchase American Depositary Shares ("ADRs") | +2,473 | 2,473 | ||
| 2025-12-16 | Neal James R Director | Purchase · Pre-Funded Warrants to purchase ADRs | +2,473 | $0.40 | $999 | 2,473 |
| 2025-12-16 | Neal James R Director | Purchase · Warrants to purchase ADRs | +3,093 | 3,093 | ||
| 2025-12-16 | Neal James R Director | Purchase · Pre-Funded Warrants to purchase ADRs | +3,093 | $0.40 | $1K | 3,093 |
| 2025-12-16 | Prudo-Chlebosz Raymond Director | Purchase · Warrants to purchase American Depositary Shares ("ADRs") | +618,658 | 618,658 | ||
| 2025-12-16 | Prudo-Chlebosz Raymond Director | Purchase · Pre-Funded Warrants to purchase ADRs | +618,658 | $0.40 | $250K | 618,658 |
| 2025-12-16 | Prudo-Chlebosz Raymond Director | Purchase · Warrants to purchase ADRs | +386,661 | 386,661 | ||
| 2025-12-16 | Prudo-Chlebosz Raymond Director | Purchase · Pre-Funded Warrants to purchase ADRs | +386,661 | $0.40 | $156K | 386,661 |
Page 3 of 11 · 216 trades